EHA 2019 | Update on ERIC’s CLL studies and initiatives
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, gives an update on the work of the European Research Initiative on CLL (ERIC). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Transcript (edited for clarity)
ERIC at the European research initiating on CLL, is planning and conducting a number of research. In particular in our tradition in the past years we are very keen on performing real world evidence studies, and we just recently publish a work on the use of Bendamustine plus
ERIC at the European research initiating on CLL, is planning and conducting a number of research. In particular in our tradition in the past years we are very keen on performing real world evidence studies, and we just recently publish a work on the use of Bendamustine plus Rituximab in second-line. We are now going to publish one in first-line, and compare it to the novel therapies. In other studies that we recently launched, is the study of the use of Obinutuzumab alone even if not indicated, or in combination with Chlorambucil all over Europe including Israel. ERIC is also promoting education, so we are organizing a number of workshops in particular related to the techniques for genetic testing in CLL. And, for the first time this year we organized one in the US in collaboration with our friends and colleagues at NIH. And, we indeed organized the first immunoglobulin workshop to educate about the use of immunoglobulin gene analysis in stratification of a patient with CLL.
Read more...
